| NCT ID | NCT07248163 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bioray Laboratories |
| Condition | Non-hodgkin Lymphoma,B Cell |
| Study Type | INTERVENTIONAL |
| Enrollment | 6 participants |
| Start Date | 2025-03-11 |
| Primary Completion | 2027-08-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 6 participants in total. It began in 2025-03-11 with a primary completion date of 2027-08-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-center, single-arm, open-label clinical study, and the sample size is set to 3-6 subjects.
Eligibility Criteria
Inclusion Criteria: 1. Willing to participate in this clinical study and sign an informed consent form; 2. Age ≥ 18 years old; 3. Estimated survival time ≥ 3 months; 4. At least one measurable lesion; 5. CD19 positively expressed; 6. ECOG score 0-1； 7. Hematology, coagulation and biochemistry parameters meeting the requirements; 8. LVEF ≥ 55%; 9. No severe pulmonary disorders; Exclusion Criteria: 1. Pregnant or lactating women; 2. Subjects who previously received allogeneic cell therapies, including allogeneic stem cell transplant; 3. Subjects who previously received anti-CD19 targeted therapy; 4. Prior treatment with any CAR-T cell product or other genetically modified T cell therapies; 5. History of Richter's transformation of chronic lymphocytic leukemia (CLL); 6. Presence of uncontrollable fungal, bacterial, viral, or other infections requiring systemic therapy; 7. Subjects with positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and peripheral blood HBV DNA titer higher than the upper limit of detection; hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; human immunodeficiency virus (HIV) antibody positive; syphilis test positive; 8. Severe mental disorders; history of CNS disorders (e.g., epileptic seizure, cerebrovascular ischemia/hemorrhage, dementia, cerebellar diseases, or any CNS-involved autoimmune disorders); 9. Active autoimmune disorders requiring immunotherapy, including but not limited to end organ damages caused by autoimmune disorders (e.g., Crohn's disease, rheumatoid arthritis, and systemic lupus erythematosus) in the past 2 years, or requiring systemic application of immunosuppressive drugs or other drugs for systemic control of diseases; 10. Primary immunodeficiency; 11. History of other malignancies; 12. Patients with severe cardiovascular disorders; 13. Any circumstances that possibly increase the risk of subjects or interfere with the study results as judged by the investigator.
Contact & Investigator
Ping Li, phD
📞 13564181131
Frequently Asked Questions
Who can join the NCT07248163 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non-hodgkin Lymphoma,B Cell. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07248163 currently recruiting?
Yes, NCT07248163 is actively recruiting participants. Visit ClinicalTrials.gov or contact Bioray Laboratories to inquire about joining.
Where is the NCT07248163 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07248163 clinical trial?
NCT07248163 is sponsored by Bioray Laboratories. The trial plans to enroll 6 participants.